HEALTHglobal
STAT+: Medicare chief says TrumpRx is meant to be narrow in scope
Single source
Updated 3 hours ago
First seen March 20, 2026 20:49:25Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Today's biotech news includes the Medicare director offering a tempered view of TrumpRx and high-dose Wegovy getting an FDA nod.